Jane Street’s 4D Molecular Therapeutics FDMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.45M Buy
+171,009
New +$2.22M ﹤0.01% 4807
2026
Q2
– Sell
-39,694
Closed -$387K – 12002
2026
Q1
$370K Sell
39,694
-185,209
-82% -$1.61M ﹤0.01% 8755
2025
Q4
$1.69M Buy
224,903
+107,988
+92% +$1.1M ﹤0.01% 5138
2025
Q3
$1.02M Sell
116,915
-73,458
-39% -$439K ﹤0.01% 6284
2025
Q2
$706K Buy
190,373
+49,494
+35% +$174K ﹤0.01% 6285
2025
Q1
$455K Sell
140,879
-69,945
-33% -$330K ﹤0.01% 7053
2024
Q4
$1.17M Buy
210,824
+65,312
+45% +$513K ﹤0.01% 5068
2024
Q3
$1.57M Buy
145,512
+11,987
+9% +$199K ﹤0.01% 4963
2024
Q2
$2.8M Buy
133,525
+104,014
+352% +$2.61M ﹤0.01% 3918
2024
Q1
$940K Buy
29,511
+4,016
+16% +$102K ﹤0.01% 5534
2023
Q4
$517K Sell
25,495
-21,429
-46% -$282K ﹤0.01% 6702
2023
Q3
$597K Buy
46,924
+5,141
+12% +$86K ﹤0.01% 6006
2023
Q2
$755K Buy
+41,783
New +$769K ﹤0.01% 5677
2023
Q1
– Sell
-36,306
Closed -$706K – 9273
2022
Q4
$806K Buy
+36,306
New +$561K ﹤0.01% 5321

Other funds holding FDMT

Jane Street's FDMT Position: Q3 2026 in Review

Jane Street opened a new position in 4D Molecular Therapeutics (FDMT) in Q3 2026: 171,009 shares worth $2.45M. The stake represents ﹤0.01% of the portfolio and ranks #4807 among its holdings. This is a return to the name: Jane Street previously reported a position in FDMT as recently as Q1 2026.

Jane Street first reported a position in FDMT in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.8M in Q2 2024. 167 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.

  • Jane Street held 171,009 shares of 4D Molecular Therapeutics worth $2.45M as of Q3 2026.
  • 4D Molecular Therapeutics was a new Jane Street position in Q3 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #4807 holding.
  • Jane Street first reported a position in 4D Molecular Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Jane Street's 4D Molecular Therapeutics position peaked at $2.8M in Q2 2024.
  • 167 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.